Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04753658 · ClinicalTrials.gov registry record
Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 15
- Enrollment target
NCT04753658 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 15 participants.
The verdict
NCT04753658 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 15 participants
- Enrollment target
Study Summary
The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.
Interventions
- DRUG lorlatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2022-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04753658
The ClinicalTrials.gov registry entry for NCT04753658 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lorlatinib is the first listed.
NCT04753658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04753658 about?
NCT04753658 is a clinical study titled "Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib". The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.
What is the current status of trial NCT04753658?
This trial is currently terminated. The enrollment target is 15 participants. The study started on 2021-03-19. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT04753658?
The interventions under investigation include: lorlatinib (DRUG).
Who is sponsoring clinical trial NCT04753658?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.